Survival with first-line bosentan in patients with primary pulmonary hypertension

European Respiratory Journal

Volumn 25, Issue 2, 2005, Pages 244-249

  McLaughlin, V V ^a   Sitbon, O ^b   Badesch, D B ^c   Barst, R J ^d   Black, C ^e   Galie N ^f   Rainisio, M ^g   Simonneau, G ^b   Rubin, L J ^h  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF COLORADO   (United States)

^d College of Physicians and Surgeon ^*  (United States)

^e ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g ACTELION PHARMACEUTICALS LTD   (Switzerland)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bosentan; Endothelin receptor antagonists; Primary pulmonary hypertension; Pulmonary hypertension; Survival

Indexed keywords

AMINOTRANSFERASE; BOSENTAN; ILOPROST; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNIPROST;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DIZZINESS; DYSPNEA; FEMALE; FLUSHING; HEADACHE; HEART FAILURE; HEART PALPITATION; HUMAN; INFORMATION PROCESSING; KAPLAN MEIER METHOD; LEG EDEMA; LIMB PAIN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PREDICTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REGISTER; RHINOPHARYNGITIS; SIDE EFFECT; SURVIVAL RATE; THORAX PAIN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WALKING; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RESPIRATORY FUNCTION TESTS; SULFONAMIDES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 13844280943     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00054804     Document Type: Article

References (16)

1. Fuster V, Steele PM, Edwards WD. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587.
2. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival of primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
3. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. New Engl J Med 1996; 334: 296-301.
4. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
5. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
6. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123.
7. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
8. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension. A 1-year follow-up study. Chest 2003; 124: 247-254.
9. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
10. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-223.
11. Sandoval J, Bauerle O, Palomar A, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994; 89: 1733-1744.
12. Barst RJ, McGoon M, McLaughlin VV, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.
13. Badesch DB, Abman SN, Ahearn G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based guidelines for clinical practice. Chest 2004; 126: Suppl. 1, 35S-77S.
14. Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
15. McGinn TG, Guyatt GH, Wyer PC, Naylor CD, Stiell IG, Richardson WS. Users' guides to the medical literature: XXIII: how to use articles about clinical decision rules. Evidence-based Medicine Working Group. JAMA 2000; 284: 79-84.
16. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: Suppl. 1, 78S-92S.